CBDV (cannabidivarin): an emerging cannabinoid

CBDV belongs to the family of so-called "propyl" cannabinoids, as does THCV, which differ from the more common molecules (CBD, THC) by a shorter side chain. This structural difference slightly alters its affinity for the body's receptors, without making it psychoactive (source: literature).

Hemp produces it naturally, but in marginal quantities. According to the available scientific reviews, CBDV rarely exceeds 1% of the plant's dry weight, which makes it a so-called "minor" cannabinoid, markedly less abundant than CBD or CBG.

Preclinical studies, carried out on animal models, suggest anticonvulsant potential for CBDV (source: 2023-2024 reviews). This work belongs to a wider field of research on cannabinoids and neuronal activity, in which CBD itself has been the subject of extensive investigation.

It is essential to keep these results in perspective. An observation in animals, in the laboratory, does not automatically transpose to humans. No therapeutic indication has been validated to date for CBDV, and no product may lawfully claim one.

CBD remains by far the best-documented non-psychoactive cannabinoid, with a body of clinical studies far larger than that for CBDV. CBDV, for its part, remains an emerging research subject, with data still limited on its precise mode of action in humans.

In practical terms, the low natural concentration of CBDV in the plant also makes large-scale extraction difficult, which explains its rarity in the products currently on sale, compared with the availability of conventional CBD oils (see our article on the sublingual method for CBD oil).

Research on CBDV remains at an exploratory stage. The publications available between 2023 and 2024 confirm the scientific interest in this molecule, without, however, establishing conclusions applicable to the general public (source: 2023-2024 reviews).

Consumers curious about minor cannabinoids such as CBDV should bear in mind that the literature is still young. CBD, whose dose-dependent profile is better characterised, notably through work discussed in our article on the biphasic effect of CBD, enjoys a level of documentation that CBDV has not yet reached.

Is CBDV psychoactive?

No, CBDV is a non-psychoactive cannabinoid, like CBD (source: literature). It does not produce the "high" associated with THC.

Is there much CBDV in hemp?

No, it rarely exceeds 1% of the plant's dry weight, which makes it a minor cannabinoid (source: scientific reviews). Its extraction therefore remains limited compared with that of CBD.

Can CBDV treat epilepsy?

No claim of that kind is permitted: the available studies are preclinical, carried out on animal models (source: 2023-2024 reviews). They open up a line of research, not a validated medical indication.

Can you buy CBDV products in France?

CBDV-only products remain rare on the French market because of the molecule's low natural concentration in the plant. Most available products remain centred on CBD, which is better documented and more readily available.